reason report
rimegep stori initi op rate
pt
bottom line initi op rate sotp-
base pt invest thesi four-fold think
migrain space signific market brand acut
segment underappreci biohaven monet strong
rimegep clinic profil like commerci partner
potenti go alon strategi glutam platform/pipelin
get minim attent due signific investor focu cgrp
platform compani multipl shot goal area
could sourc upsid recent in-licens product
multipl system atrophi nice sale
opportun given recent deal complet
product convers yet manag strong
scientif background neurosci expect use busi
develop continu build pipelin
catalyst watch includ data long-term safeti
studi rimegep acut migrain top-lin data
studi rimegepant/zydi file nda
nurtec al phase studi complet
rett syndrom ema feedback eu file
requir rimegep acut migrain
leerink proprietari research underscor conclus
proprietari research report includ insight medacorp
physician interview rimegep medacorp physician
survey analys pp migrain space rimegep
 rett syndrom sotp analys
compani financi model pp respect
pt base sotp analysi forecast cash flow
discount rate risk invest
thesi rimegep may get approv liver toxic
emerg side effect rimegep label may cgrp
class black box warn liver toxic even issu doesnt emerg
clinic trial acut market smaller forecast due
lack differenti gener triptan and/or payer restrict
wors expect biohaven struggl compet
larger competitor allergan op lilli choos go alon
investor skeptic biohaven glutam pipelin
sinc prior fail phase trial sca need work
anoth indic valid pipelin assum
compani need rais capit execut product launch
link industri report initi neurosci sector
full coverag univers
sotp cash flow
net debt total capit
year price history/av daili volume mil
creat bluematrix
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
rx trend deriv im health
biohaven pharmaceut initi outperform pt
tabl content
invest thesi compani
rimegep migrain
glutam mpo-i pipelin
invest thesi
invest thesi four-fold
think migrain space signific market brand acut segment underappreci
biohaven monet strong rimegep clinic profil potenti go alon strategi
like commerci partner
glutam platform/pipelin get minim attent signific focu calcitonin gene-
relat peptid cgrp platform compani multipl shot goal area could sourc
recent in-licens product multipl system atrophi nice opportun
sale given recent deal finish product even convers yet
manag strong scientif background neurosci expect continu use busi
develop continu build pipelin
pt base sotp analysi forecast cash flow discount rate
rimegep may get approv may get black box warn liver toxic signal emerg clinic trial
rimegep label may still get black box warn liver toxic due fda appli full cgrp class even
issu doesnt emerg clinic trial
acut market smaller forecast due lack differenti gener triptan and/or payer restrict
higher expect
biohaven struggl compet larger competitor allergan lilli choos go alon
investor skeptic glutam pipelin sinc phase trial failur spinocerebellar ataxia sca
assum compani need rais capit execut product launch
clinical-stag biopharmaceut compani focus rang neurolog diseas rare disord
found
us
cgrp platform potenti significantli chang
migrain treatment paradigm oral inhal
version rimegep
glutam platform underappreci
multipl shot goal pipelin
troriluzol riluzol prodrug ocd sca ad
gad
nurtec al
newli licens asset sept expand portfolio
therapi area rare neurolog disord
multipl system atrophi
multipl stock-mov catalyst expect next year
timelin key near-term mileston
file nda al
start phase trial sca
file nda acut migrain
studi nation institut
start phase trial gad
potenti fda approv acut
clinical-stag biopharmaceut compani focus rang neurolog diseas rare disord
rimegep lead driver sale forecast
troriluzol potenti platform-in-a-drug
depend least one indic work
believ ocd less overal risk ad
substanti de-risk aim approv
symptomat treatment first longer risker
need clinic data physician
excit potenti rett syndrom
believ efficaci differenti multipl
compani target rett syndrom
recent licens interest
expans portfolio bring new moa
late-stag asset pipelin along new
nich rare neurodegen diseas target
financi valuat
compani report leerink estim
product non-risk adj revenu stage developmentnon-risk adj npv probabl successrisk-adj npv expect launchrisk-adj net current valu share cgrprimegep us acut migrain us acut migrain us amyotroph later sclerosi us obsess compuls disord us alzheim diseas us gener anxieti disord us rett syndrom multipl system atrophi adj risk-adj risk-adj total asset count fulli dilut assum two fund rais risk-adjust equiti valu exclud unalloc account corpor technolog franchis valu howev valu includ net cash adjust sotp valuat breakdown product indicationrimegepantu us -alstroriluzoleu -ocd ad -net adjustmentg aadjustmenttot biohaven pharmaceut hold compani ltd
asset
us
us ocd
us ad
us gad
us rtt
us
us
us ad
us rtt
us
us
 us
 us al
us ocd
us ad
us gad
 us rtt
 us
po use
us
us ocd
us ad gad
us rtt
us
us
us ad
us rtt
us
us
 us
 us al
us ocd
us ad gad
 us rtt
 us
item shown view sotp valuat
compani report leerink estim
stock close
po probabl success acut migrain ad alzheim diseas gad gener anxieti disord
biohaven stock focus rimegep recent
compani report leerink estim factset data
data long-term safeti studi
top-lin data studi start feb phase
finish enrol studi start dec phase
finish phase studi oral solid dose form phase
ema feedback europ file requir pre-market
data phase studi fund nih
finish enrol phase trial prevent
safeti data combo studi nivolumab
pembrolizumab
overview debat
larg us
acut migrain
bullish us acut migrain market
forecast market grow
bullish oral cgrp opportun base
posit feedback medacorp physician
survey multipl physician discuss henc
assum oral cgrp grab market
share rimegep captur
oral cgrp trx result sale
risk
liver toxic oral cgrp
lack differenti
payer restrict wors
biohaven struggl compet
larger competitor
payer drive price
kind market
share rimegep
take
non-
migrain asset
pipelin
think non-cgrp asset get minim
earli stage asset
attent point multipl shot
goal glutam asset troriluzol
nurtec go multipl platform-expand
indic augment migrain
franchis interest
shot goal ad pipelin
troriluzol fail phase
trial sca
anxieti rett syndrom
execut in-
think manag done nice job
far bd leverag strong scientif
background neurosci seiz
opportun larg pharma seek
divest asset longer fit portfolio
biohaven need keep make
neurosci high risk field
compani report leerink estim medacorp physician interview physician survey migrain sept neurologist migrain specialist
rimegep
rimegep oral highli select cgrp antagonist first develop
acut treatment migrain soon migrain prevent treatment
what
one oral option cgrp class acut migrain bring robust efficaci
improv safeti triptan placebo-lik liver safeti far better
ubrogep manag two formul zydi fast-dissolv intranas formul
cgrp receptor antagonist whose action result inhibit pain transmiss decreas arteri
dilat block neurogen inflamm
individu list tabl includ without
attribut drug related drug-rel seriou advers event
sae subject sae rimegep group placebo
group dose onset sae
primari endpoint hour pain free bothersom symptom two phase trial
compani plan file nda potenti oral zydi fast-dissolv format
us composit matter patent hemisulf salt rimegep expir februari
includ potenti patent term extens
forecast peak sale
larg us acut migrain
view bullish us acut migrain market forecast
market grow
acut market larg
rx us
market growth
sinc
three new product
enter market drive
market share
slightli lower
ubrogep higher
lasmiditan share
forecast rimegep
base
physician feedback
growth assumpt
total acut market
leerink estim iqvia data trx medacorp physician survey migrain sept neurologist migrain specialist
acut migrain growth migrain triptan brand lilli migrain triptan brand lilli growth total sacut market share acut total sale million biohaven pharmaceut hold compani ltd
larg us acut migrain
medacorp physician view physician excit new cgrp
sometim troubl differenti payer biggest hurdl
medacorp physician believ high unmet need across migrain patient mani
either given current drug much success current medic
larg unmet
need migrain
physician less satisfi acut treatment option high comfort
level triptan appreci triptan cheaper gener
physician top concern around triptan overus caus patient progress
sever migrain cardiovascular issu patient suscept heart condit
physician excit
multipl new agent
next year
medacorp physician excit new drug come specif migrain
interest cgrp mechan known work treatment
patient cant use
triptan like first
user new oral cgrp
physician note larg unmet need patient triptan failur and/or
contraind cardiac issu prevent patient use triptan
physician could see oral cgrp becom prefer product triptan
note depend long-term liver toxic safeti data
much differenti
medacorp physician consid rimegep allergan ubrogep similar agent
base data note prefer would depend real-world experi
long-term safeti
insur coverag
biggest hurdl new
cgrp seen
medacorp physician interview
major physician note insur coverag aimovig biggest hurdl
patient run two month free drug physician offic need spend mani
hour work prior author pa put place payer involv record
standard letter phone call push even one approv
patient pa go physician said would cost offic extra
think trend would like happen newli approv cgrp drug
kind market share rimegep take peak sale
view assum oral cgrp grab market share
rimegep captur oral cgrp trx result sale
efficaci support rimegep approv acut migrain
two phase studi rimegep demonstr statist signific clinic meaning higher patient
pain freedom hour freedom mb hour vs placebo
singl dose rimegep without rescu medic superior placebo pain freedom pain relief hour
post-dos demonstr increas improv trend beyond hour
appear result increment better compar oral cgrp ubrogep think
would support fda approv acut migrain given need efficaci option triptan
ubrogep freedom mb photophobia
phonophobia pain relief measur
far know rimegep acut cgrp
sustain pain relief hour thu far
ubrogep provid type data
data singl dose rimegep rescu med
data kaplan-mei estim pain freedom subject
censor took rescu med lost follow-up
biohaven studi studi valu placebo-adjust freedom mb relief rescu med freedom relief freedom relief relaps disabl bothersom symptom photophobia phonofobia nausea sp sustain pain pain freedom defin patient transit moderate-to-sever pain no-pain pbo placebo rimeg rimegep ubro ubrogep valu neg drug group improv upon placebo rateallergan achiev iacut treatment migrain phase dataallergan achiev ii biohaven hold compani ltd
kind market share rimegep take peak sale
view assum oral cgrp grab market share
rimegep captur oral cgrp trx result sale
safeti support rimegep approv acut
rimegep well toler demonstr liver safeti profil similar placebo across two phase trial fact
liver level uln rimegep arm better placebo arm
contrast allergan ubrogep demonstr slight differ placebo achiev ii trial howev
physician survey dont see larg differ safeti two oral cgrp
phase clinic studi oral cgrp acut migrain signal signific hepatotox per hy law
think oral cgrp acut migrain shown significantli lower toxic level seen merck
telcagep ultim end program believ bode well potenti fda approv drug
howev big question remain whether fda appli black box warn oral cgrp ye physician
indic would neg impact prescrib materi
alt ast
measur
hepatox
case dose
safeti board deem four case
relat ubro remain
case deem possibl relat
treatment
case
relat ubro
ubro ubrogep rimeg rimegep uln upper limit normal hy law defin alt ast bilirubin total alp
kind market share rimegep take peak sale
view assum oral cgrp grab market share
rimegep captur oral cgrp trx result sale
rimegep better sumatriptan term
time pain recurr
rimegep better sumatriptan term
time pain relaps
patient previous moderate/sever pain
patient pain free hr post dose
show pain relief hr post dose experienc
return moderate/sever pain hr
return pain mild moder sever hr
overal higher likelihood patient
higher likelihood patient take
take sumatriptan pain relaps
sumatriptan pain recurr
among public data rimegep oral cgrp compar data vs triptan trial power
assess statist signific still believ show compel posit benefit/risk profil favor rimegep
physician compar triptan cgrp acut migrain rimegep head start facilit prescrib
provid phase data wherea ubrogep done
kind market share rimegep take peak sale
medacorp survey survey indic higher acut therapi use
sever patient mani physician look forward prescrib oral cgrp
current treatment landscap acut migrain
patient receiv acut treatment migrain
current prescrib acut
treatment migrain
among survey physician
migrain patient receiv treatment acut
episod last month
due combo use percentag may sum
migrain headach day per month neither patient receiv
acut treatment fit chronic episod categori includ
medacorp physician interview medacorp physician survey migrain sept neurologist migrain specialist
physician prescrib triptan patient
gener indic acut use
howev prefer option
analgesics/nsaid addit low efficaci
physician satisfi ergot safety/efficaci
ask futur prescrib oral cgrp
assum patient tri triptan physician would
prescrib patient think conserv
believ come real-world efficaci
safeti whether oral cgrp black box warn
kind market share rimegep take peak sale
medacorp survey survey suggest physician favor oral cgrp
acut migrain think cgrp modestli better safeti vs triptan
ubrogep efficaci seen similar rimegep
ubrogep safeti seen similar rimegep
review clinic data physician see
differ efficaci rest evenli split prefer
even higher proport physician thought ubrogep
rimegep similar safeti
physician percept oral cgrp efficaci data
physician percept oral cgrp safeti data
rimegep superior efficaci vs
rimegep modestli better
rimegep similar efficaci vs
rimegep modestli wors
rimegep inferior efficaci vs
rimegep superior safeti vs
rimegep modestli better safeti
rimegep similar safeti vs
rimegep modestli wors safeti
rimegep inferior safeti vs
oral cgrp efficaci seen similar triptan
oral cgrp safeti seen modestli better triptan
major physician think oral cgrp rimegep
atogep ubrogep similar efficaci compar
triptan stronger prefer evenli split
physician percept oral cgrp efficaci vs triptan
oral cgrp superior triptan
oral cgrp modestli better
oral cgrp similar triptan
oral cgrp modestli wors
oral cgrp inferior triptan
physician think oral cgrp safeti profil similar
modesti better triptan think cgrp superior safeti
physician percept oral cgrp safeti vs triptan
oral cgrp superior triptan
oral cgrp modestli better
oral cgrp similar triptan
oral cgrp modestli wors
oral cgrp inferior triptan
medacorp physician interview medacorp physician survey migrain sept neurologist migrain specialist
kind market share rimegep take peak sale
medacorp survey survey indic black box warn oral cgrp
could neg impact prescrib
impact black warn oral cgrp
black box effect physician prescrib
effect chang rx
minim effect decreas rx
moder effect decreas rx
moder larg effect decreas rx
major effect decreas rx
physician
concern
cgrp
liver toxic
major physician indic would
decreas rx moder larg effect oral cgrp
black box warning/class label liver toxic
concern level rank scale
concern extrem concern
believ sale potenti oral cgrp atogep prevent rimegepant/ubrogep acut depend
whether receiv black box warn
physician indic somwhat concern liver toxic
rimegep shown low level liver enzym elev close placebo phase trial none
met hy law criteria sever hepatox still unclear fda treat label
medacorp physician interview medacorp physician survey migrain sept neurologist migrain specialist
kind market share rimegep take peak sale
view view zydi addit opportun
differenti migrain space help support rimegep well
zydi intranas rimegep
addit formul help differenti
rimegep cgrp
would expand cgrp platform
unpreced high solubl high free
biohaven collabor zydi
fraction make uniqu among cgrp
uniqu freeze-dri oral tablet dispers nearli instantli
mouth water requir
featur make ideal nasal inhal
subcutan also oral formul
think zydi version rimegep ad
conveni patient
biohaven also develop intranas form
think low cost good small molecul
optim safeti profil high dose build strong case
use acut migrain
seen triptan differ formul tablet nasal
conserv estim peak non-risk
spray etc well receiv patient vastli
differ routin acut treatment need
know work readi file
zydi use
product launch countri
line data acut migrain met
data could includ
nda file
thu far allergan appear
pursu fast-dissolv option
ubrogep
tablet websit
compani report leerink estim medacorp physician interview
biohaven plan use
potenti rapid
onset effect
differenti
rimegep zydi
kind market share rimegep take peak sale
forecast non risk-adjust sale
assum gross price
assum asp
sale estim base
medacorp survey migraine/headach specialist
medacorp kol call
market share
lower ubrogep
higher
compani report leerink estim medacorp physician interview medacorp physician survey migrain sept neurologist migrain specialist
acut migrain triptan brand lilli market share biohaven pharmaceut hold compani ltd
glutam mpo-i
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
compar older riluzol
al patient
reduc risk
common nmda target agent
well toler healthi
sale non risk-adjust valu
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset multipl upcom phase trial
nurtec sublingu riluzol custom-design address multipl limit riluzol believ approv path
straightforward moa alreadi valid al nurtec address unmet need deliveri efficaci
troriluzol robust preclin evid show effect riluzol ad ocd gad ad troriluzol
seek conserv develop pathway risk profil approv much lower compar mani
glutam mechan action
biohaven one glutam
signal mediat
modul glutam way
may neuroprotect
increas releas brain
biohaven two glutam
increas activ eaat
increas glutam clearanc
decreas glutam releas
pre-synapt neuron
eaat glutam
transport depend
electrochem gradient
sodium ion function
channel may inhibit
releas glutam
biohaven focus develop therapi help normal glutam process way treat specif diseas
glutam deep role present brain synaps
abnorm glutam releas dysfunct glutam clearanc caus overstimul glutam receptor
lead danger neural injuri call excitotox associ wide rang neurodegen diseas
depress al anxieti dementia rett syndrom seizur dementia spinocerebellar ataxia
troriluzol novel gener prodrug riluzol multipl shot
goal potenti approv sca ocd gad and/or mild-to-moder ad
what
troriluzol new-and-improv version older drug rilutek riluzol improv bioavail
safeti absorpt conveni dose absorb yield lower drug burden
thu could potenti portfolio-in-a-drug asset approv treatment multipl larg neurolog diseas
glutam transport modul mean prevent dysfunct glutam releas and/or clearanc
caus overstimul neural excitotox believ act glutam transport
phase studi spinocerebellar ataxia sca
riluzol preclin data ad
benefit ad
believ
troriluzol
well given
current enrol two phase clinic trial one treatment ad one treatment ocd
second phase clinic trial sca expect earli result expect open-label
week extens studi sca
sever patent famili contain claim prodrug riluzol method use treat al sca
depress diseas grant patent would expir
forecast non risk-adjust sale sale
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
think least one troriluzol shot goal could potenti work
manag deep
experi glutam
ceo vlad coric
first report
therapeut effect
riluzol neuropsychiatr
also led first clinic
fluid biomark identifi
enrich patient
prodrom ad
made good bd
decis far
believ compani
get credit
rimegep bhv-
in-licens
bristol bristol
divest non-oncolog
asset appear
smart move far
think licens
troriluzol yale
except
licens asset
stage data make easi
biohaven hit
ground run
research contribut
troriluzol
troriluzol solid
clinic oper
troriluzol four
vast prodrug librari
candid
select multipl
advantag featur
arriv troriluzol
troriluzol result
year drug discoveri
research
alway case small
preclin data
prior riluzol studi
help valid moa
troriluzol low
royalti high margin
biohaven strateg
keep cost low
clinic trial troriluzol
glutam modul
fda approv
al neuroprotect
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
think phase trial miss sca end
think ocd opportun appeal
despit miss troriluzol show direct benefit
high unmet need larg popul
oct readout troriluzol didnt separ placebo
primari endpoint p-valu secondari outcom
howev troriluzol favor safeti well toler
low discontinu rate seriou
rational continu research
riluzol studi publish romano et al show
ssri adjunct use atyp antipsychot
patient inadequ respons
novel moa fda approv ocd
two decad
statist signific efficaci sca patient vs placebo
ocd preval us popul
manag indic failur may variabl
subject part scale assess rate ataxia
sara score failur screen patient wide
score swing baselin period
long-term data show separ natur histori cohort
earli data suggest troriluzol could work ocd
yale research pilot data suggest effect ocd
statist signific effect adjunct use
riluzol vs placebo adult refractori ocd
moa link benefit ocd
clinic data suggest dysregul glutam
play key role normal brain function may
contribut underli caus ocd troriluzol
modul pathway
caveat data need human trial
depend whether biohaven prove clinic effect
caveat sca rare investig diseas sara
score unvalid score system need modif
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
gad chronic excess worri restless fatigu
multicent us random double-blind placebo-
control trial outpati gad
impair abil function social work
irrit bowel-lik gastrointestin issu
patient
gad affect adult us popul yet
primari outcom chang ham-a baselin wk
activ receiv treatment
gad often co-occur major depress disord mdd
us estim treatment resist
argument troriluzol potenti approv gad
note yale ip protect riluzol gad sad panic disord
anti-anxieti effect riluzol appear similar
benzodiazepin anim model believ safeti
profil troriluzol significantli better vs diazepam
trend preclin model demonstr riluzol anti-
anxieti effect improv recognit memori
compani report leerink estim anxieti depress associ america sugiyama et al phsychopharmacolog sugiyama et al brain behav
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
think troriluzol moa could work alzheim diseas
glial cell failur earli sign ad
pathophysiolog troriluzol impact
glial cell protect neuron fail
associ neuron cell death anim
gfap marker glial cell failur increas
anim model ad age
core featur glial cell failur impair
glutam transport function
clinic literatur suggest glial failur
occur amyloid tau failur
imag ad brain suggest distinct neg chang
glutamin synthesi gs vs healthi brain
immunoreact ir tempor neocortex area
ad group significantli weaker control group
implic ad pathophysiolog
year ad
compani report leerink estim ugbod et al biochem journal hosi et al neuropatholog appli neurobiolog
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
preclin data show riluzol multipl clinic
benefici effect ad anim model
believ troriluzol benefit
namenda aim right label
rescu cognit symptom learn memori
namenda act postsynapt neuron
attenu impair hippocamp glutam synaps
increas neuron spine densiti aged-and-tr anim
reduc amyloid tau build
work weak nmda
antagonist strong nmda antagonist
total block effect debilit side
contrast troriluzol act regul
transport increas
activ express glutam without
directli act receptor
provid improv safety/toler profil
importantli biohaven go label
symptomat treatment ad first
indic
studi symptomat shorter
prodrom ad
screen failur rate accur diagnosi
patient
thu think symptomat smarter low
non-migrain asset pipelin underappreci
obsess compuls disord
patient
ocd us
sever
inadequ
respons soc
activ
forecast non risk-adjust sale
use asp
sale estim base manag discuss
compani report leerink estim medacorp physician interview
nurtec sublingu oral disintegr tablet formul
riluzol develop treatment al
what
could signific improv standard care rilutek al patient due
predict pk perform easier administr need fast prior take medic
reduc side effect due reduc liver exposur
glutam nmda receptor antagonist block neuron releas glutam neurotransmitt
essenti transmit inform neuron play crucial role normal brain function
result pivot bioequival studi
confirm sublingu
mg bioequival exposur rel
pre-specifi primari analysi bhv-
achiev area-under-the-curv
peak exposur
respect compar gener
gener riluzol
complet phase studi test pk safeti toler jan read posit data
pivot bioequival studi compar sublingu formul riluzol oral tablet
compani prepar file nda fda via pathway
grant patent famili use pain al depress expir may elig
orphan exclus conting show clinic superior rilutek/riluzol
forecast non risk-adjust sale
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
riluzol rilutek approv
al sinc sever issu
multipl advantag
soc riluzol brand rilutek
improv bioavail absorpt
twice dose requir low
fast requir hours/day
taken meal
dose depend liver effect
prevent use higher dose
one approv indic two
lower overal drug burden liver
potenti multipl formul
cautious optimist nurtec al substanti benefit soc mechan action
valid al could offer conveni formul sever al patient
howev physician may differenti gener riluzol nurtec and/or long-term safeti unclear may mimic similar
issu riluzol
first class low-trap nmda receptor antagonist oral
prodrug iv drug lanicemin
what
low-trap antagonist avoid dissoci effect common nmda target agent
make good option treat orphan neural diseas rett syndrom
block glutam signal mediat nmda receptor modul glutam
way may neuroprotect via increas releas brain neurotroph factor bdnf
nonclin toxicolog experi lanicemin
pharmacolog dose lanicemin elicit advers effect
learn memori attent rat dog small
increas heart rate blood pressur high dose
high dose neuron degener seen
phase singl
dose mg
studi well toler
neuron find link glutam antagonist
find consist nmda receptor antagonist
ketamin thu lanicemin advanc clinic trial
toxicolog studi week rat dog
reveal find consist lanicemin expect
given neglig concentr compar
activ metabolit lanicemin
enrol single-ascend dose multiple-ascend dose trial goal complet phase
trial oral solid dose formul end
issu patent relat use lanicemin expir patent applic use
neurolog diseas use/structur prodrug would expir issu
forecast non risk-adjust sale
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
think potenti rett syndrom
random control trial lanicemin
show target engag efficaci
efficaci demonstr treatment resist
depress primari secondari outcom
effect also sustain beyond dose period
expand therapeut window
blocker bind open state
nmda channel
may trap end
deep channel
lead dissoci
high-trap agent
ketamin narrow
therapeut window low
expand window
lanicemin activ
ingredi
carri rett syndrom
cautious optimist potenti rett lanicemin evid clinic effect
broad therapeut window still lack human clinic trial data epilepsy-lik diseas rett syndrom
howev comfort fact manag strong experi know-how around glutam modul
track record make smart spend decis
non-migrain asset pipelin underappreci
view think multipl shot goal glutam
asset recent in-licens interest asset
onset
loss hand/speech skill impair gait
mutat
none expect multipl competitor
next year
off-label therapi treat multipl
current prescrib drug rett syndrom
top three prescrib drug rett syndrom patient
keppra onfi lamict notabl onfi went gener oct
could creat opportun
accord physician rett syndrom
patient refractori believ earli
candid use new agent
recogn key risk multipl late-stag pipelin asset
target rett could launch
medacorp physician survey epilepsi sept neurologist epileptologist leerink estim
biohaven pharmaceut led season manag team
chief execut offic biohaven sinc novemb
year drug discovery/clin develop experi yale bristol-my squibb
involv multipl drug develop program drug abilifi opdivo
daklinza sunvepra
work across therapeut area includ neurosci oncolog immuno-oncolog virolog
chief medic offic biohaven sinc novemb
year experi neurosci research within academia yale industri
work assoc director clinic scienc led multipl
program major depress
work group director clinic develop group bristol-my squibb
chief offic biohaven sinc may
previous work alexion execut director financ north america
year financ experi includ year within pharmaceut industri
bristol-my squibb schering-plough alexion
year research experi studi pain mechan includ year pharma
experi drug discoveri develop multipl posit bristol-my squibb
led bristol biolog program effort cgrp receptor antagonist year
part develop team advanc rimegep clinic
biohaven balanc sheet million except per-shar asset receiv expens current method asset stockhold equitycurr liabilitiesaccount payabl net current liability/futur royalti equiti equitycommon paid-in comprehens losstot stockhold liabil stockhold biohaven hold compani ltd
biohaven million except per-shar oper activitiesnet compens interest valu conting equity/ warrant fair valu warrant/derivative/conting equiti method oper asset use oper invest activitiescapit market use invest financ activitiesproce prefer chang common stock net chang note chang debt net use financ equival begin equival end biohaven hold
